YEAR                                                         EVENTS
 1907 - The Company was Incorporated at Vadodara.  The Company
        manufacture chemicals, pharmaceuticals, injections,
 penicillin,
        antibiotics, sulphuric acid, superphosphate and other
        fertilisers, generating electricity, manufacture of
 electronic
        items, running of hospitals and health care units, etc.
 
 1938 - The authorised capital was Rs 20 lakhs divided into 10,000-6
 1/4%
        preference shares of Rs 100 each and 10,000 No. of equity
 shares
        of Rs 100 each.  5,000 preference shares and all equity
 shares
        were issued and subscribed.
 
 1942 - 5,000-6% preference shares were issued and subscribed.
 
 1944 - The authorised capital was increased to Rs 50 lakhs by the
        creation of 30,000 shares of Rs 100 each out of which 3,000
        shares were classified as equity shares and issued to the
        shareholders in the proportion 3:10.
 
 1946 - The Company issued 2,000 No. of equity shares as rights at a
        premium of Rs 150 per share in the proportion 2:13.
 
 1947 - 5,000 unclassified shares were converted into equity, shares
 and
        they were issued as rights at a premium of Rs 150 per share
 in
        the proportion 1:3.
 
 1948 - 5,000 unclassified shares were converted into equity shares
 and
        issued as bonus in the proportion 1:4.
 
 1949 - The authorised capital was increased to Rs 1 crore by creation
 of
        5,000-6% third preference shares of Rs 100 each and 45,000
        unclassified shares of Rs 100 each.  Further 7,000
 unclassified
        shares were converted into equity shares and issued as bonus
 in
        the proportion of 2:3 irrespective of class.
 
 1958 - The authorised, issued and paid-up capital stood at Rs
 100,00,000
        and Rs 80,00,000 respectively as at 31st December.
 
 1959 - 20,000 Right Equity shares offered at par in prop. 1:4 to all
        classes.  In 1961, 10,000 Right Equity shares offered at par
 in
        prop. 1:1 to classes.
 
 1962 - 9,500 Bonus equity shares issued in prop; 1:10, 40,000 Right
        Equity shares offered at a prem. of Rs 30 per share in the
 prop.
        4:11 irrespective of class.
 
 1966 - In Dec. 48,167 Bonus Equity shares issued in prop. 1:3. 
 12,278
        No. of equity shares issued without payment in cash to
 members
        of Alembic Distributors Ltd., Mumbai and Alembic distributing
        Agency, Bangalore on their merger.
 
 1967 - The amalgamation on Alembic Distributors, Ltd., with the
 Company
        from 1st January, was sanctioned by the High Courts of
 Ahmedabad
        and Mumbai.  The Scheme of Amalgamation of Neomer Ltd. with
 the
        Company from the appointed date 1.1.1983 was approved by the
 High
        Court of Gujarat by its Order dated 12.9.1986.
 
 1968 - 25,080 Right Equity shares issued at par in prop. 5:41.
 
      - In March 1971, 57,487 Right Equity shares issued at par in
 the
        prop. 1:5.
 
 1977 - 6 1/4% Pref. and 6% III Pref. shares converted to 9%
 redeemable
        Pref. shares from 1.1.1976.  5,000-5% Pref. shares redeemed
 at
        Rs 105 per shares on 1.1.1977.
 
 1979 - The Company issued 75,000 secured debentures of Rs 100 each
 as
        rights to augment the resources of working capital.
 
 1980 - Redeemed 1,000 Pref. shares each on 1.1.1978, 1.1.1979,
        1.11.1980, 1.1.1981, 1.1.1982 and 1.1.1983.
 
 1985 - 2,000 Pref. shares redeemed. 66,900 No. Equity shares
 allotted
        without payment in cash to the shareholders of Neomer, Ltd.
 on
        its merger.  2,000 Pref. shares redeemed.
 
 1989 - A variety of new products were introduced under group Feed
        Supplements and Tonics which were well received in the
 market.
 
      - The Panpharm Division was started at village Panelav in
        Panchmahal district of Gujarat State to undertake manufacture
 of
        formulations.
 
 1990 - A new quinolone antibacterial drug Ciprofloxacin was
 introduced
        in the market.
 
      - The Veterinary Division introduced certain new farm products
 like
        ascal, ruman bolus etc. during the year.
 
      - New products such as ginseng preparation and zinc and
 vitamin-B
        complex preparations were introduced in the market.
 
      - 100,000-14% non-convertible debentures were issued.  These
        debentures are redeemable in three yearly instalments
 commencing
        from 11th May, 1995 with redemption premium of 5% payable
 along
        with the last instalment.
 
 1991 - As a result of the research and development activities, the
        company developed Roxithronycin, a newer generation bulk
 drug.
 
 1992 - The veterinary division introduced Cloxacillin Amoxicillin
        injections.
 
      - Introduction of Cloxacillin Amoxicillin injection in the
 market.
 
 1993 - The Expansion of Penicillin capacity to 1000 MMU together
 with
        integrated effluent treatment plant was undertaken and series
 of
        steps were taken to instal diesel engine driven compressors
 for
        constant air supply etc.
 
      - The erstwhile Neomer, Ltd. had a licensed capacity to
 manufacture
        6000 mt. polypropylene staple fibre.  In addition to this, it
 was
        registered with D.G.T.D. for the manufacture of 1000 mt. per
        annum. of polypropylene multifilament yarn.
 
      - Under the broad banding policy, Neomer had obtained permission
 to
        manufacture other synthetic filament yarn i.e. polyester and
        nylon yarn including industrial yarn/tyre cord.
 
      - The company introduced a revolutionary antibiotic
 Azithromycin
        which is used in tissue directed antibiotic therapy.
 
 1995 - With a view to facing this eventuality the company proposed
 to
        install gas turbine based captive Co-generations Power Unit at
 a
        total outlay of Rs 25 crores.
 
      - Two large pencillin fermentors were installed and
 commissioned.
 
      - Algen, Ltd. is a subsidiary of the Company.  As at 31st Dec.
        10,007 No. of equity shares out of 10,013 No. of equity shares
 of
        Rs 10/- each issued by the subsidiary were held by the
 Company.
 
      - 164,732 No. of equity shares of Rs 100 each at a premium of
 Rs
        850/- per share issued to the shareholders on rights basis.
 
 1996 - 10,00,000 Pref. shares allotted on preferential basis.
 
 1997 - The performance of the pharmaceutical division was affected
 by
              Governmental basis imposed on scrip to pencillin
 formulation
               which affected the major brand of the company.
 
            - The Company introduced Nimegesic Gel an important
 topical item.
              The Company introduced Rorid liquid for paediatric use,
 a ready
              made suspension of Roxithromycin.  The Company
 strengthened its
              position by the introduction of Clarithro and basic
 manufacture
              of clarithromycin.
 
           - The company installed Peniccillin - Gas 600 m.m.u. per
 annum and
              Erythromycin 100 tpa.  Also, a second line of extraction
 facility
              for erythromycin was installed.
 
           - The Alembic Herbals veterinary, a new division of
 veterinary
              business was launched in June.
 
           - The Company issued 10,00,000-16% redeemable
 non-convertible
              cumulative preference shares of Rs 100 each.  These are
              redeemable at par on 11.2.1999.
 
           - The Company has expanded its reach in the fastest growing
 analgesics and
              anti-inflammatory segment with the launch of new
 molecules Rofecoxib and 
              Celecoxib.
 
 2000 - The Company has launched Glycodin Activ Cold & Flu Tablets.
 
 2001 - The Company has launched its version of sildenafil citrate,
 under the brand name 
             `Asigra'.  The pill for erectile dysfunction is in two
 dosage forms of 25 mg and 50 mg
              as against three by most of the other players.
 
            - The Company has launched a new OTC brand, Glycodin Activ
 cold and flu tablets.
 
 2002
 
 -Gujarat High court sanctions for the merger of Bulk Drug unit of M/s
 Darshak Ltd with the company.
 
 -Enters into an in-licensing pact with Euroresearch for introducing
 Gelfix Collagen dressing sponge pads in the country. 
 
 -Appoints Mr Nitin Jaywant as the President, Active Pharmaceutical
 Ingredients division.
 
 -Floats a new division called 'SynX' to cater to patients suffering
 from condition called Syndrome X .
 
 -Enters into a research pact with Chiron Corporation of US for
 contract research.
 
 -Gets approval from DCGI to manufacture and market Cefetamet Pivoxil
 tablets.
 
 -Ties up with Italian Pharma company, Euroresearch  to bring its
 products to India.
 
 2003
 
 -Launches 4th generation injectable Cephalosporin Cefepime under the
 brand name of Cepime.
 
 -Allots equity shares to the shareholders of M/s Darshak Ltd as per
 the scheme of demerger.
 
 -Acquires brand and trade mark rights of obstretical care drug
 Yutopar from Solvay Pharmaceuticals BV, Netherlands.
 
 -Launches new division for research and development services, BioArc
 Research Solutions.
 
 -Forays into speciality therapeutics segment.
 
 -Signs agreement with two MNC companies for R & D division.
 
 -Lines up a rights issue of Rs.32.37crs.
 
 -Alembic Limited has informed the Exchange that the company has
 despatched the Offer Document and Composite application form to all
 the shareholders on December 22, 2003. The Rights Issue is going to
 open on December 30, 2003, the last date for receiving requests for
 split forms is January 13, 2004 and the Rights Issue will close on
 January 28, 2004.
 
 -The comnpany raised Rs 10 crore by placing 90-day commercial paper
 (CP) at 4.85 per cent with a mutual fund on March 8th.
 
 -Alembic signs MoU with Xechem International
 
 
 2005
 
 - Launches a no-calorie sugar substitute, `Zero',  on February 2,
 2005.
 
 2008
 
 - Alembic Ltd has informed that the Company has acquired API
 manufacturing unit of Nirayu Pvt Ltd. situated at Panelav, P.O.
 Tajpura, Taluka Halol, Dist. Panchmahals, Gujarat.